Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

SOPHiA GENETICS (SOPH) Notes Payables (2020)

SOPHiA GENETICS's Notes Payables history spans 1 years, with the latest figure at $2.9 million for Q4 2020.

On a quarterly basis, Notes Payables changed N/A to $2.9 million in Q4 2020 year-over-year; TTM through Dec 2020 was $2.9 million, a N/A change, with the full-year FY2020 number at $2.9 million, changed N/A from a year prior.
Notes Payables hit $2.9 million in Q4 2020 for SOPHiA GENETICS.
Over the last five years, Notes Payables for SOPH hit a ceiling of $2.9 million in Q4 2020 and a floor of $2.9 million in Q4 2020.